Nuclear extracts from teniposide (VM-26)-resistant sublines of the human leukemic cell line CCRF-CEM have decreased levels ofDNA topoisomerase Il catalytic activity and decreased capacity to form drug-stabilized covalent protein-DNA complexes. The ATP concentration required for equivalent activity in a DNA-unknotting assay is 2-to 8-fold higher in nuclear extracts from drug-resistant cell lines as compared with the parental line. When adenosine 5' -[B,Yimidoltriphosphate is substituted for ATP in complexformation assays, no significant change is seen with drugsensitive cells, but a 50-65% reduction is seen with VM-26-resistant cells. Collectively, these results indicate that an alteration in ATP binding may be involved in the resistance phenotype. Therefore, we identified regions of the topoisomerase II sequence that conform to previously identified nudeotide-binding sites. Starting with cDNA as the template we determined the sequence of the topoisomerase II mRNA surrounding these sites by sequencing DNA fragments produced by the polymerase chain reaction. In the region corresponding to the consensus B ATP-binding sequence described by DNA topoisomerase II is an essential nuclear enzyme that catalyzes the interconversion of topological forms of doublestranded DNA (1-3). This activity is required for DNA replication, recombination, and chromosome segregation (1, 4) . The cDNA sequence of a topoisomerase II from HeLa cells (5) corresponded to a 174-kDa protein (170-kDa form). A second distinct form of topoisomerase II having an apparent molecular mass of 180 kDa has been identified (6). The 170-kDa form is more sensitive to the topoisomerase II inhibitors teniposide and merbarone than the 180-kDa form and the two forms differ in their cleavage site, thermal stability, and inhibition by A+T-rich oligonucleotides (7). Chung et al. (8) Several classes of antitumor drugs, including the anthracyclines, epipodophyllotoxins, and aminoacridines, inhibit the catalytic activity of topoisomerase 11 (9-14), and both rodent and human cell lines have been selected for resistance to these drugs (15-21). In most cases cells that have been selected for resistance to a single topoisomerase II-inhibiting drug are cross-resistant to drugs of the other classes. This type of multidrug resistance, termed at-MDR, has been associated with an altered topoisomerase II activity (22-25) or a decrease in the amount of the enzyme (26). Previous studies of the human leukemic cell line CCRF-CEM and two VM-26-resistant sublines showed that topoisomerase II in nuclear extracts from resistant cells required a higher concentration of ATP than an equal amount of topoisomerase II from sensitive cells to achieve equivalent P4 DNA unknotting (20, 25) . Also, only with extracts from the sensitive cells could adenosine 5'-[/3,'y-imido]triphosphate substitute for ATP to increase covalent topoisomerase II-DNA complexes in the presence of VM-26 or 4'-(9-acridinyl)aminomethanesulfon-m-anisidide (m-AMSA). To characterize this altered ATP interaction at the DNA level, consensus sites for nucleotide interaction were identified in the topoisomerase II sequence, and the sequences flanking these sites in the VM-26-resistant cells were determined. A single base change was identified by comparison with the wild-type topoisomerase II sequence.
imidoltriphosphate is substituted for ATP in complexformation assays, no significant change is seen with drugsensitive cells, but a 50-65% reduction is seen with VM-26-resistant cells. Collectively, these results indicate that an alteration in ATP binding may be involved in the resistance phenotype. Therefore, we identified regions of the topoisomerase II sequence that conform to previously identified nudeotide-binding sites. Starting with cDNA as the template we determined the sequence of the topoisomerase II mRNA surrounding these sites by sequencing DNA fragments produced by the polymerase chain reaction. In the region corresponding to the consensus B ATP-binding sequence described by Walker et al. [Walker, J. E., Saraste, M., Runswick, M. J. & Gay, N. J. (1982) EMBO J. 1, 945-951], the cDNA from the two VM-26-resistant sublines contained an altered sequence having a G -) A base change. This base substitution results in the replacement of the conserved arginine at position 449 with a glutamine. Hybridization with allele-specific oligonucleotides confirmed the presence of both the normal and the altered sequence in the resistant cell lines, whereas only the normal sequence was found in the sensitive CEM cells. A chemical mismatch cleavage procedure for the detection of mispaired bases in DNA duplexes identified no other alterations in the 5' third of the mRNA coding sequence, which contains the complete ATP-binding domain of topoisomerase II. The presence of mRNA encoding topoisomerase II with Gln"9 correlates both with the presence ofa topoisomerase II protein whose interaction with ATP is altered and with increased resistance to the cytotoxicity of VM-26.
DNA topoisomerase II is an essential nuclear enzyme that catalyzes the interconversion of topological forms of doublestranded DNA (1) (2) (3) . This activity is required for DNA replication, recombination, and chromosome segregation (1, 4) . The cDNA sequence of a topoisomerase II from HeLa cells (5) corresponded to a 174-kDa protein (170-kDa form). A second distinct form of topoisomerase II having an apparent molecular mass of 180 kDa has been identified (6) . The 170-kDa form is more sensitive to the topoisomerase II inhibitors teniposide and merbarone than the 180-kDa form and the two forms differ in their cleavage site, thermal stability, and inhibition by A+T-rich oligonucleotides (7). Chung et al. (8) Several classes of antitumor drugs, including the anthracyclines, epipodophyllotoxins, and aminoacridines, inhibit the catalytic activity of topoisomerase 11 (9) (10) (11) (12) (13) (14) , and both rodent and human cell lines have been selected for resistance to these drugs (15) (16) (17) (18) (19) (20) (21) . In most cases cells that have been selected for resistance to a single topoisomerase II-inhibiting drug are cross-resistant to drugs of the other classes. This type of multidrug resistance, termed at-MDR, has been associated with an altered topoisomerase II activity (22) (23) (24) (25) or a decrease in the amount of the enzyme (26) . Previous studies of the human leukemic cell line CCRF-CEM and two VM-26-resistant sublines showed that topoisomerase II in nuclear extracts from resistant cells required a higher concentration of ATP than an equal amount of topoisomerase II from sensitive cells to achieve equivalent P4 DNA unknotting (20, 25) . Also, only with extracts from the sensitive cells could adenosine 5'-[/3,'y-imido]triphosphate substitute for ATP to increase covalent topoisomerase II-DNA complexes in the presence of VM-26 or 4'-(9-acridinyl)aminomethanesulfon-m-anisidide (m-AMSA). To characterize this altered ATP interaction at the DNA level, consensus sites for nucleotide interaction were identified in the topoisomerase II sequence, and the sequences flanking these sites in the VM-26-resistant cells were determined. A single base change was identified by comparison with the wild-type topoisomerase II sequence.
MATERIALS AND METHODS
Cell Culture and Nucleic Acid Isolation. CEM and VM-26-resistant cells were cultured and selected as described (20, 27) . DNA (28) , total cellular RNA (29) , and poly(A)+ mRNA (30, 31) were prepared as described. cDNA was synthesized from 1-5 jig of poly(A)+ mRNA with 3' specific or random primers by using the Lambda Librarian kit (Invitrogen, San Diego (Fig. 4) (Fig. 5, lanes  4 and 5) . The other weak bands in the sample lanes are nonspecific, as they are also present in the unreacted controls (lanes 1 and 2) .
DISCUSSION
Topoisomerase II in nuclear extracts from VM-26-resistant CEM cells differs from the enzyme in extracts from sensitive CEM cells in the concentration of ATP required for maximum catalytic activity in the DNA-unknotting assay and in the effect of a nonhydrolyzable analog of ATP, adenosine 5'-[p,ly-imido]triphosphate, on the formation of complexes (20, 25) . We have used three independent methods to demonstrate and confirm that a mutant allele for the topoisomerase II gene is expressed in the VM-26-resistant CEM cells.
This G --A mutation at position 1346 results in mRNA coding for a topoisomerase II protein with glutamine at residue 449 instead of the normal arginine. In other topoisomerase II proteins the analogous position is always arginine or lysine. Fig. 6 shows the homology of the topoisomerase II sequence flanking the alteration site in 10 species (36, 50) . Tamura and Gellert (48) Chemical mismatch cleavage analysis of topoisomerase II for nucleotide base alterations. Sensitive-and resistant-cell topoisomerase II cDNA was analyzed for base-pair mismatches. The table indicates the cell line from which the cDNA was synthesized, the specific primer that was labeled (5' primer or 3' primer), and the chemical treatment used to detect mismatched bases. amino acid at the start of the consensus B segment (Fig. 6) . The conservation of this positively charged amino acid suggests it may be critical in maintaining the structure or function of the ATP-binding fold.
In the well-studied adenylate kinase protein (47, 51) , the A and B consensus segments form a pocket where ATP binds and is hydrolyzed (51, 52) . The negatively charged amino acid at the end of the B sequence may serve to bind to the (8 and y phosphate of ATP through the chelated Mg24 (52). In topoisomerase II, this amino acid would be Glu4W, which is (20) . However, the amount of topoisomerase II associated with the nuclear matrix is decreased in the VM-26-resistant cells (57) .
Cytogenetics of the Drug-Resistant Cells. The gene for human topoisomerase II has been mapped to chromosome 17q21-q22 (5). The CEM parental cells are near triploid (n = 87; ref. 58 ) and the two resistant cell lines have three or four copies of chromosome 17 (M. B. Qumsiyeh, W.T.B., and D.P.S., unpublished observations). The mutation would not be expected to be present in all ofthe chromosomes 17, which is consistent with expression of both the normal and the mutant topoisomerase II sequence in the CEM/VM-1 and CEM/VM-1-5 cell mRNA. The presence of both sequences was confirmed both by direct sequencing and by hybridization of normal and mutant ASOs (Figs. 2 and 3) . Therefore, it is not necessary for the cells to have a complete deficiency of the normal protein to express the resistance phenotype. One hypothesis is that the level of resistance is proportional to the level of the mutant topoisomerase II.
That the VM-26-resistant phenotype is present in cells that express both a normal and mutant allele for topoisomerase II is intriguing from the standpoint of studies involving formation of somatic cell hybrids between the VM-26-resistant and -sensitive CEM cells (59) . The IC50 values for three of four hybrid cell lines selected were equal to or only slightly higher than the sensitive parental line, consistent with a recessive phenotype. However, one of the hybrids displayed an IC50 that was >13-fold increased relative to sensitive cells. There was also a reduced level of covalent topoisomerase 11-DNA complex formation in one hybrid line. These observations are consistent with our present finding of expression of both normal and altered topoisomerase II mRNA resulting in a drug-resistant phenotype. The increased sensitivity of the hybrid cells could result from an increased ratio of normal to mutant topoisomerase II alleles or from loss oftopoisomerase II alleles by chromosome segregation. It will be important to determine whether the mutant allele is present and expressed in the hybrid lines.
Single Allelic Mutation and Homodimer Formation. Topoisomerase II functions as a homodimer (60, 61) and thus is subject to dominant negative mutations (62 
